Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 31, 2020 at 11:02 AM.

  1. #1 cafead, Mar 31, 2020 at 11:02 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,024
    Likes Received:
    3
    via A new CAR-T therapy may be coming. And maybe $9 per share for Celgene investors, too.

    Bristol Myers Squibb announced they submitted an NDA for the multiple myeloma “ide-cel” CAR-T therapy Celgene developed in partnership with bluebird. The therapy is one of the three that has to be approved to unlock the BMS-Celgene contingent value agreement that would give shareholders of the absorbed NJ company $9 per share. The first, ozanimod, was approved last week. The second, a CAR-T treatment for non-Hodgkin’s lymphoma called liso-cel, was submitted to the FDA in December.

    article source
     
    Quote

Reply to Thread